medigraphic.com

2018, Number 4

<< Back

Rev Mex Med Repro 2018; 8.9 (4)

Ovarian reserve after oncological treatment in patients with breast cancer

Vargas-Hernández VM, Ventura-Quintana V, Tovar RJM

Language: Spanish
References: 39
Page: 138-148
PDF size: 459.45 Kb.


ABSTRACT

Objective: To determine the gonadal damage of patients with breast cancer after chemotherapy.
Material and Method: A prospective and comparative observational study of patients with history of breast cancer who received chemotherapy (group 1), chemotherapy and radiotherapy (group 2), independently of surgical treatment and 4 patients without cancer, control group (group 3), was performed. Hormone follicle hormone was determined, antral follicular count and ovarian volume with color Doppler ultrasound.
Results: There were included 14 patients in different clinical stages of breast cancer, we found that chemotherapy and radiotherapy decreased the follicular count, mainly when both were administered; with significant damage in groups 1 and 2; the follicle stimulating hormone levels increased in groups 1 and 2 with respect to the control group, without differences in the tests and the different chemotherapy schemes, all caused ovarian damage and ovarian dysfunction.
Conclusion:: It was observed a significant diminishment of ovarian reserve in patients submitted to chemotherapy alone or with radiotherapy assessed by levels of basal FSH, follicular count and ovarian volume.


REFERENCES

  1. Merlo DF, Ceppi M, Filiberti R, Bocchini V, Znaor A, Gamulin M, et al. Breast Impact incidence trends in European women aged 20-39 years at diagnosis. Breast Cancer Res Treat 2012;134(1):363-70.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66(1):7-30.

  3. Rodriguez, S., Campo-Engelstein, L., & Emanuel, L. Fertile future? Potential social implications of oncofertility. J Clin Oncol 2013;31(6):665-667.

  4. Clarisa R. Gracia and Jacqueline S. Jeruss. Lives in the balance: Women with cancer and the right to fertility care. J Clin Oncol 2013:20;31(6):668-669.

  5. Salama M, Mallmann P. Emergency fertility preservation for female patients with impact: clinical perspectives. Anticancer Res 2015;35(6):3117-3127.

  6. Anderson RA, Nelson SM, Wallace WH. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas 2012;71:28-33.

  7. Kruszyńska A, Słowińska-Srzednicka J. Anti-Müllerian hormone (AMH) as a good predictor of time of menopause. Prz Menopauzalny 2017;16(2):47-50.

  8. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol 2016;12(20):2333-2344.

  9. Spressão M, Oliani AH, Oliani D. Value of the ultrasound in the Study of Ovarian Reserve for Prediction of Oocyte Recovery. Rev Bras Ginecol Obstet 2016;38:499-505.

  10. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.

  11. Vargas Hernández VM, Vargas Aguilar VM, Tovar Rodriguez JM Cáncer de mama en mujeres adolescentes y en edad reproductiva en Vargas- Hernández VM. 1ª. ed. Cáncer en la Mujer, Edit. Alfil México, 2011:1777-1783.

  12. Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, et al. Ovarian function after chemotherapy in 20 impact breast survivors. Curr Oncol 2017;24(6):e494- e502.

  13. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, Marques RJ. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early stage breast impact: a systematic review and meta-analysis JAMA Oncol 2016;2(1):65-73.

  14. Johnson JA, Tough S. Society of Obstetricians and Gynaecologists of Canada. Delayed child-bearing. J Obstet Gynaecol Can 2012;34(1):80-93.

  15. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Prevention of chemotherapy-induced ovarian damage. Fertil Steril 2016;105(1):20-9.

  16. Balachandren N, Davies M. Fertility, ovarian reserve and cancer Maturitas 2017;105:64-68.

  17. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016;14:1.

  18. Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation– ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives. Hum Reprod 2017;32(9):1802-1811.

  19. Ahmed S, Sherif Sh, Tamer A, Hesham A and Odette W. Antral 21mpacto f count is a better indicator for the assessment of ovarian reserve. Evidence Based Women’s Health J 2012;2:126-132.

  20. Anderson RA, Cameron DA. Pretreatment serum antimüllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast impact. J Clin Endocrinol Metab 2011;96(5):1336-43.

  21. de Fine Licht S, Rugbjerg K, Gudmundsdottir T, Bonnesen TG, Asdahl PH, Holmqvist AS, et al. Long-term inpatient disease burden in the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study: A cohort study of 21,297 childhood impact survivors. PloS Med 2017;14(5):e1002296.

  22. Demeestere I, Brice P, Peccatori FA, et al. Gonadotropinreleasing hormone agonist for the prevention of chemotherapy- induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-909.

  23. Gerber B, Ortmann O: Prevention of Early Menopause Study (POEMS): Is it possible to preserve ovarian function by gonadotropin releasing hormone analogs (GnRHa). Arch Gynecol Obstet 2014;290:1051-1053.

  24. Ganesh S, Lye MS, Lau FN. Quality of life among breast cancer patients In Malaysia Asian. Pac J Cancer Prev 2016;17(4):1677-1684.

  25. Hamish W, Wallace B. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer 2011;117(10 suppl):230;1-10.

  26. Kishk EA, Mohammed Ali MH. Effect of a gonadotropinreleasing hormone analogue on cyclophosphamideinduced ovarian toxicity in adult mice. Arch Gynecol Obstet 2013;287(5):1023-9.

  27. Welsh LC, Taylor A. Impact of pelvic radiotherapy on the female genital tract and fertility preservation measures. World J Obstet Gynecol 2014;3(2):45-53.

  28. Ghadjar P, Budach V, Köhler C, Jantke A, Marnitz S. Modern radiation therapy and potential fertility preservation strategies in patients with cervical impact undergoing chemoradiation. Radiot Oncol 2015;10:50.

  29. Mazeron R, Maroun P, Cao K, Mbagui R, Slocker-Escarpa A, Chargari C, Haie-Meder C. Impact of radiotherapy on female fertility. Bull Cancer 2015;102(5):470.

  30. Letourneau JM, Smith JF, Ebbel EE, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer 2012;118(18):4579-4588.

  31. Sukumvanich P, Case LD, Van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: a prospective study. Cancer 2010;116:3102-11.

  32. Green DM, Sklar CA, Boice JD, Jr., Mulvihill JJ, Whitton JA, Stovall M et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-81.

  33. Venturella R, Lico D, Sarica A, Falbo MP, Gulletta E, Morelli M, et al. OvAge: a new methodology to quantify ovarian reserve combining clinical, biochemical and 3D-ultrasonographic parameters J Ovarian Res 2015;8:21.

  34. Bozza C, Puglisi F, Lambertini M, EO, Manno M, Del Mastro L. Anti-Müllerian hormone: determination of ovarian reserve in early breast cancer patients Endocrine-Related Cancer 2014;21:R51-R65.

  35. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction. Acta Obstet Gynecol Scand 2015;94(10):1056-63.

  36. Jirge PR. Ovarian reserve tests. J Hum Reprod Sci 2011;4(3):108-113.

  37. Kim H, SK, JR, KJ, Suh CS, SH. Fertility preservation for patients with breast cancer: The Korean Society for Fertility Preservation clinical guidelines. Clin Exp Reprod Med 2017;44(4):181-186.

  38. Li F, Turan V, Lierman S, Cuvelier C, De Sutter P, Oktay K. Sphingosine-1- phosphate prevents chemotherapyinduced human primordial follicle death. Hum. Reprod 2014;29(1):107-113.

  39. Roness H, Kashi O, Meirow D. Prevention of chemotherapyinduced ovarian damage. Fertil Steril 2016;105(1):20-29.




2020     |     www.medigraphic.com